Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 31 May 2024, including: ASCO preview; Asahi Kasei Corporation’s US acquisition; Novartis AG aims for renal disease dominance; paying for gene therapies; and US BIOSECURE Act diluted.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "ASCO Preview: Five Presentations To Watch Out For" - Scrip, 23 May, 2024.)
(Also see "Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy" - Scrip, 28 May, 2024.)
(Also see "Novartis Aims To Dominate Rare Renal Disorders" - Scrip, 25 May, 2024.)
(Also see "Could Combining Strategies Be A Way Forward To Pay For Gene Therapies?" - Scrip, 28 May, 2024.)
(Also see "BIOSECURE Act Diluted Significantly, But China Plus Strategy Still Accelerating: Strides MD" - Scrip, 24 May, 2024.)
